Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,701–8,800 of 15,747
Ergun, T., Tekin, S. H., Sengün, O. A., Çakıcı, Ö. A., Seçkin, D., Adıay, C., Enül, H., Yilmaz, S., Ay, P., Haklar, G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.052 · Cited by 7
Breast Milk Conferred Immunity to Infants Against COVID-19
Richard, R. M., Maziashvili, G., Tran, M., Ramos, I. M., Laxman, A. S., & Didbaridze, N. D. N. (2023) · Cureus · doi:10.7759/cureus.42075 · Cited by 7
“As a result, the lack of data on this specific demographic has hampered the development of evidence-based recommendations, ultimately resulting in the exclusion of pregnant women from vaccine rollout plans [5,6].”
BackgroundA survey of mechanisms underlying current and potential COVID‐19 vaccines
Hebel, C., & Thomsen, A. R. (2022) · Apmis · doi:10.1111/apm.13284 · Cited by 7
“6, BNT162, Pfizer/BioNTech) [57] and 94.”
InfluentialCornforth, F., Webber, L., Kerr, G. K., Dinsdale, H., Majeed, A., & Greengross, P. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231157017 · Cited by 7
Engineering Delivery Technologies for Optimizing mRNA Vaccines
Gu, T., Yan, X., & Liu, S. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00032 · Cited by 8
An Informative Discussion for School Nurses on COVID-19 mRNA Vaccine
Gordon, J., Reynolds, M., & Barnby, E. (2021) · NASN School Nurse · doi:10.1177/1942602x21999606 · Cited by 8
mRNA Technology in Modern Medicine: Review and Future Prospects
Silva, H. M. (2025) · Clinical and Molecular Epidemiology · doi:10.53964/cme.2025001 · Cited by 4
Martín‐Arranz, M. D., Ramírez, L. G., Arranz, E. M., Vega, D. M., García, J. L. R., Azofra, M. S., Cordón, J. P., Belda, J. N., Martínez-Meco, T. V., Miguel, P. B. S., et al. (2022) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2022.9101/2022 · Cited by 6
Revolutionizing Chikungunya Vaccines: mRNA Breakthroughs With Molecular and Immune Simulations
Masum, M. H. U., Mahdeen, A. A., & Barua, A. (2025) · Bioinformatics and Biology Insights · doi:10.1177/11779322251324859 · Cited by 11
Kim, H. J., Yun, H. J., Kim, J., Kym, S., & Choi, Q. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.012 · Cited by 8
Hospital admissions due to COVID-19 in Scotland after one dose of vaccine
Dean, N. E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00765-0 · Cited by 6
Chernyavskiy, P., Richardson, J. W., & Ratcliffe, S. J. (2021) · medRxiv · doi:10.1101/2021.05.28.21257946 · Cited by 6
“In equation (1), are the coefficients of time-fixed covariates, and are the coefficients”
BackgroundCostard‐Jäckle, A., Schramm, R., Fischer, B., Rivinius, R., Bruno, R. R., Muller, B. Z., Zittermann, A., Boeken, U., Westenfeld, R., Knabbe, C., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02075-2 · Cited by 7
“Vaccines against coronavirus disease 19 (COVID-19) have been proven to be safe and highly efficient, showing robust immunogenicity and protection against severe disease manifestation [1, 2].”
BackgroundRecent advances in freeze-drying technologies for mRNA vaccines against infectious diseases
Lou, J., Wu, Z., Cheng, Y., Li, M., Liu, N., Wang, Z., Gao, X., Zheng, A., & Zhang, H. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126426 · Cited by 12
Kratzer, B., Trapin, D., Gattinger, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10030374 · Cited by 6
Navigating post-vaccine COVID-19 futures in the health and economic context
MacIntyre, C. R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00126-2 · Cited by 6
COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful?
Raslan, M. A., Raslan, S. A., Shehata, E. M., Mahmoud, A. S., Sabri, N. A., Alzahrani, K. J., Alzahrani, F. M., Alshammeri, S., Azevedo, V., Lundstrom, K. H., et al. (2023) · Vaccines · doi:10.3390/vaccines11020214 · Cited by 7
Szebeni, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040450 · Cited by 9
“The observed severe AEs were claimed to have a “low incidence” in both groups that were similar to those caused by other viral vaccines [19].”
InfluentialTan, A. Y., Chang, C., Yu, Y.-K., Low, Y. X., Razali, N. F. M., Tey, S., & Lee, S. (2022) · Vaccines · doi:10.3390/vaccines10040509 · Cited by 6
“In resonance with other studies, we found that systemic side effects were more common and severe in the second dose compared to the first dose [11,13].”
BackgroundResultInfluentialRahadi, D. A., Yusri, E., Putra, S. P., Semiarty, R., Pertiwi, D., & Ilmiawati, C. (2023) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.23.077 · Cited by 7
“In clinical trials, several vaccines have been shown to have favorable safety and efficacy, and new vaccines have also been tested for novel SARS-CoV-2 variants [10-14].”
BackgroundResultHIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies
Gravett, R. M., & Marrazzo, J. M. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00562-1 · Cited by 8
Chen, S., Kowalewska, J., & McCune, T. R. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.11.001 · Cited by 6
“edu VACCINATION against coronavirus disease 2019 (COVID-19) has played a primary role in reducing the spread of the novel coronavirus infection and in reducing the associated morbidity and mortality [1].”
Importance of outbreak response research in bridging knowledge gaps on emerging infectious diseases
Breiman, R. F., Osoro, E., Reithinger, R., Wang, D., Diamond, M., A, W. C. V. V., Wasserheit, J. N., Rabinowitz, P. M., Mboup, S., Hemingway‐Foday, J., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018297 · Cited by 7
“Review available diagnostics and interventions (therapeutics, vaccines, behavioural, policy).”
Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development
Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 8
Zhou, Z., Shen, J., Zhao, M., Zhang, X., Wang, T., Li, J., & Zhao, X. (2023) · BMC Public Health · doi:10.1186/s12889-023-15118-8 · Cited by 6
“Younger people may be more likely to report adverse reactions than older people [15, 16, 18, 21, 53].”
BackgroundMethodNew-Onset Amyotrophic Lateral Sclerosis in a Patient who Received the J&J/Janssen COVID-19 Vaccine
Feghali, E. J., Challa, A., Mahdi, M. A., Acosta, E., & Jackson, J. (2023) · Kansas Journal of Medicine · doi:10.17161/kjm.vol16.18969 · Cited by 7
Mucosal delivery of RNA vaccines by Newcastle disease virus vectors
García‐Sastre, A. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.10.001 · Cited by 7
“One of the greatest success in the history of vaccination has been the rapid generation and deployment of mRNA vaccines able to prevent hospitalization and severe disease by SARS-CoV-2, the causative agent of the COVID-19 pandemic (Polack et al., 2020; Baden et al., 2021).”
Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection
Sun, H., Su, X., Huang, L., Mu, D., & Qu, Y. (2021) · Biomolecules · doi:10.3390/biom11020196 · Cited by 6
Pascolo, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202249941 · Cited by 6
Kan, Y., Asada, M., & Uesawa, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269268 · Cited by 6
“Regarding adverse events related to mRNA vaccines, paroxysmal ventricular arrhythmia related to vaccine administration was reported in subjects aged�16 years in a clinical trial of BNT162b2, a COVID-19 vaccine developed by Pfizer and BioNTech [25], and four cases of myocardial infarction were reported in subjects aged…”
BackgroundArnold, N. D., Paper, M., Fuchs, T., Ahmad, N., Jung, P., Lakatos, M., Rodewald, K., Rieger, B., Qoura, F., Kandawa‐Schulz, M., et al. (2024) · MicrobiologyOpen · doi:10.1002/mbo3.70000 · Cited by 6
“In addition, a third ribosome ‐ associated protein, the translation inhibitor RaiA (gene ID 2297), was steadily downregulated approximately threefold at both 50°C and 55°C.”
Inflammatory and immune-mediated toxicity of lipid nanoparticles
Kim, S., Park, C., Lee, Y., Lee, K., Lee, H., & Lee, K. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119385 · Cited by 13
Hsu, C. M., Weiner, D. E., Manley, H. J., Li, N. C., Miskulin, D. C., Harford, A., Sanders, R. C., Ladik, V., Frament, J. M., Argyropoulos, C., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100718 · Cited by 6
“Previous COVID-19 status was defined by a positive SARS-CoV-2 polymerase chain reaction test at any time before the date of full vaccination or an anti-spike IgG titer ≥45 BAU/mL before or within 10 days after the first vaccine dose (representing likely undiagnosed COVID-19 at the time of initial vaccine receipt, as s…”
MethodVágó, H., Szabó, L. E., Szabo, Z., Ulakcsai, Z., Szögi, E., Budai, G., Tóth, A., Juhász, V., Dohy, Z., Hoffer, K., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.961031 · Cited by 6
Wentrys, Ł., & Stopyra, L. (2022) · Przeglad Epidemiologiczny · doi:10.32394/pe.75.28 · Cited by 6
Sun, Z., Kim, A., Sobolewski, M. D., Enick, N., Chen, C., Adams, C., Jacobs, J. L., McCormick, K. D., Mellors, J. W., Dimitrov, D. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436481 · Cited by 6
Montagud, A. C., Llenas‐García, J., Moragues, R., Pérez-Bernabeu, A., Pertegal, M. J. A., Gómez, F. J. G., Serna, A. M. G., Morante, H. G., Caballero, P., & Tuells, J. (2024) · Revista Clínica Española · doi:10.1016/j.rce.2024.01.009 · Cited by 7
Reguzova, A., Sigle, M., Pagallies, F., Salomon, F., Rziha, H.-J., Bittner-Schrader, Z., Verstrepen, B. E., Böszörményi, K. P., Verschoor, E. J., Elbers, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2832501/v1 · Cited by 6
Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA
Ulmer, J. B., & Liu, M. A. (2021) · Molecular Frontiers Journal · doi:10.1142/s2529732521400022 · Cited by 7
(2021) · doi:10.1101/2021.12.15.21267605 · Cited by 6
“351 1253 (1-241; 245-1256) WT spike (L18F/D80A/D215G/del242244/K417N/ E484K/N501Y/D614G/A701V) NA”
BackgroundVangeti, S., Periasamy, S., Sun, P., Balinsky, C. A., Mahajan, A. S., Kuzmina, N. A., Schanoski, A. S., Cooper, E. S., Beckett, C. G., Marayag, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01837-22 · Cited by 7
Chiba, S., & Shinohara, K. (2022) · Health Science Reports · doi:10.1002/hsr2.742 · Cited by 5
COVID-19 vaccination in cancer patients: Immune responses one year after the third dose
Campagna, R., Dominelli, F., Zingaropoli, M. A., Ciurluini, F., Grilli, G., Amoroso, A., Domenico, A. D., Amatore, D., Lia, M. S., Cortesi, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.03.017 · Cited by 6
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
“This class of drugs has seen substantial therapeutic progress, most notably as prophylactic vaccines for infectious diseases (Pardi et al. 2018, Polack et al. 2020, Baden et al. 2021).”
Japan COVID-19 AI team, Kataoka, Y., Kimura, Y., Ikenoue, T., Matsuoka, Y., Matsumoto, J., Kumasawa, J., Tochitani, K., Funakoshi, H., Hosoda, T., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5571 · Cited by 4
Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates
Buckley, M., Araínga, M., Maiorino, L., et al. (2024) · bioRxiv · doi:10.1101/2024.06.21.600088 · Cited by 25
Bera, K., Rojas-Gómez, R. A., Mukherjee, P., Snyder, C. E., Aksamitiene, E., Alex, A., Spillman, D. R., Marjanović, M., Shabana, A. A., Johnson, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54697-3 · Cited by 6
“Notably, two of the Food and Drug Administration (FDA) approved SARS-CoV-2 vaccines, mRNA-1273 and BNT162b, use LNPs to deliver mRNA 8,9 .”
BackgroundGagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.23.465542 · Cited by 6
Zhou, H., Xu, M., Hu, P., Li, Y., Ren, C., Li, M., Yang, P., Wang, S., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172724 · Cited by 7
Huang, Y., Shin, J. E., Xu, A. M., Yao, C., Joung, S. Y., Wu, M., Zhang, R., Shin, B., Foley, J., Mahov, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105209 · Cited by 5
Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study
Zeitoun, A., Hallit, S. R., Helali, M., Chehade, S., Allam, C., Ibrahim, A., Dimassi, H. I., & Karam, R. (2022) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-022-00459-3 · Cited by 6
“In a randomized controlled trial conducted in December 2020, a two-dose regimen of the messenger ribonucleic acid (mRNA) Pfizer-BioNTech (PZ) vaccine, showed 95% effectiveness in preventing COVID-19 infection [4].”
MethodAldali, J. A., Alotaibi, B. A., Aldali, H. J., Alasiri, G. A., Alaseem, A. M., Almuqrin, A., Alshalani, A., & Alotaibi, F. T. (2023) · Biomedicines · doi:10.3390/biomedicines11082203 · Cited by 6
“The COVID-19 vaccinations were associated with a number of mild to moderate side effects, including headaches, discomfort, edema, and redness at the injection site, as well as muscle and joint issues [10,11].”
BackgroundOver- and under-estimation of vaccine effectiveness
(2022) · doi:10.1101/2022.01.24.22269737 · Cited by 6
Optimal age-specific vaccination control for COVID-19: An Irish case study
Zavrakli, E., Parnell, A. C., Malone, D., Duffy, K. R., & Dey, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290974 · Cited by 8
“On November 9th 2020 Pfizer and BioNTech [25, 26] announced a vaccine candidate that successfully completed the clinical trials and was 90% effective in preventing infection from the virus.”
Lumbreras-Marquez, M. I., Fields, K. G., Campos‐Zamora, M., et al. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13788 · Cited by 6
FFP3 respirators protect healthcare workers against infection with SARS-CoV-2Preprint
Ferris, M., Ferris, R., Workman, C., et al. (2021) · doi:10.22541/au.162454911.17263721/v1 · Cited by 6
Morton, B., Jambo, K., Chikaonda, T., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17172.2 · Cited by 6
Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India
Majumdar, S., Verma, R., Saha, A., Bhattacharyya, P., Maji, P., Surjit, M., Kundu, M., Basu, J., & Saha, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.637362 · Cited by 9
Redondo, E., Calle, I. R., Mascarós, E., Yuste, J., Fernández-Prada, M., Ocaña, D., Jimeno, I., Gil, A., Molina, J., Díaz-Maroto, J. L., et al. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.06.005 · Cited by 6
Audiovestibular and vaccination complications of COVID-19
Gabr, T. A., Kotait, M. A., & Moaty, A. S. (2022) · The Egyptian Journal of Otolaryngology · doi:10.1186/s43163-022-00290-2 · Cited by 7
“But later, there was an increase in the frequency of patients presenting with SSNHL, tinnitus, aural fullness, and/or the exacerbation of previously stable Menière’s in addition to autoimmune inner ear disease (AIED) [63].”
BackgroundSARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites
Yang, L., Liang, T., Pierson, L. M., Wang, H., Fletcher, J. K., Wang, S., Bao, D., Zhang, L., Huang, Z. J., Zheng, W., et al. (2022) · Research · doi:10.34133/2022/9769803 · Cited by 7
Moss, S., Jurkowicz, M., Nemet, I., Atari, N., Kliker, L., Elkader, B. A., Gonen, T., Martin, E. T., Lustig, Y., Regev‐Yochay, G., et al. (2023) · Vaccines · doi:10.3390/vaccines11101624 · Cited by 6
Ahn, B., Shin, S. H., Hwang, M.-J., Choi, H., Na, S., Park, S., Lee, J. S., Choe, Y. J., Yoon, Y., Seo, K., et al. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e317 · Cited by 6
Beran, A., Mhanna, A. S., Mhanna, M., Hassouneh, R., Abuhelwa, Z., Mohamed, M. F. H., Sayeh, W., Musallam, R., Assaly, R., & Abdeljawad, K. H. (2023) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2023.2165344 · Cited by 6
“1%) had moderate to severe liver disease.(5) In the Moderna trial as well, only 196 (0.”
BackgroundCoronavirus disease 2019 vaccines and relevant adverse reactions
Chung, E. H. (2021) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2021.9.3.124 · Cited by 6
Lai, Y.-H., Chen, H.-Y., Chiu, H., Kang, Y., & Wong, S. (2022) · Vaccines · doi:10.3390/vaccines10122174 · Cited by 8
“Four studies provided data comparing the occurrence of adverse events after the first or second dose of BNT162b2 with that in the unvaccinated group [17,22,26,32].”
BackgroundResultSolaymani–Dodaran, M., Kalantari, S., Banihashemi, S. R., Es‐haghi, A., Noofeli, M., Mohazzab, A., Mokhberalsafa, L., Sadeghi, F., Mokarram, A. R., Hajimoradi, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27370 · Cited by 6
Yoon, S., Goh, H., Matchar, D. B., Sung, S. C., Lum, E., Lam, S. S. W., Low, J. G. H., Chua, T., Graves, N., & Ong, M. E. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2085469 · Cited by 8
Andersen, K. M., McGrath, L. J., Reimbaeva, M., Mendes, D., Nguyen, J. L., Rai, K. K., Tritton, T., Tsang, C., Malhotra, D., & Yang, J. (2023) · medRxiv · doi:10.1101/2023.03.17.23287415 · Cited by 5
Halvorson, T., Ivison, S. M., Huang, Q., Ladua, G. K., Yotis, D. M., Mannar, D., Subramaniam, S., Ferreira, V. H., Kumar, D., Belga, S., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004873 · Cited by 8
Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt
Hussein, A. A. R. M., Hashem, M. K., Azizeldine, M. G., & Shaddad, A. M. (2023) · Egyptian Journal of Bronchology · doi:10.1186/s43168-023-00196-4 · Cited by 10
Vasquez, D. M., Chiem, K., Silvas, J. A., Park, J., Ye, C., & Martínez‐Sobrido, L. (2021) · Journal of Visualized Experiments · doi:10.3791/63127 · Cited by 7
Spatiotemporal vaccine allocation policies for epidemics with behavioral feedback dynamics
Barth, J. R., Li, S., Aprahamian, H., & Gupta, D. (2023) · Naval Research Logistics (NRL) · doi:10.1002/nav.22142 · Cited by 8
“We assume this high-level of efficacy since the vast majority of vaccinations in the U.S. are either Moderna or Pfizer-BionTech (Baden et al., 2021; Polack et al., 2020).”
BackgroundNovak, F., Nilsson, A. C., Christensen, E. B., Stougaard, C. L., Barnkob, M. B., Holm, D. K., Witt, A. H., Byg, K., Johansen, I. S., Nielsen, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432348 · Cited by 7
Raez, L. E., Tarockoff, M., Uribe, C. R. C., Niu, J., Sareli, C., Sundararaman, N., Ion, J., Eckardt, P., Alvarez-Pinzon, A. M., & Hussein, A. M. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1667 · Cited by 6
“Finally, all efforts should be directed toward protecting cancer patients through vaccinations (11-13) or using treatments that may improve survival or reduce intensive care unit admissions through the use of steroids (14) or even IV monoclonal antibodies as treatment (15).”
BackgroundNing, F., Cao, X.-Q., Wang, Q., Li, Z., Ruan, Z., & Chang, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23944 · Cited by 5
“Multiple large randomized controlled trials (RCTs) and real-world studies have demonstrated the safety and efficacy of COVID-19 vaccines in the general population [6,7].”
García, M. T. M., Lana, Á. T., Agudo, M. B. A., et al. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.03.002 · Cited by 6
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults
Chen, G., Yu, X.-Y., Luo, L., Zhang, F., Dai, X., Li, N., Shen, Z., Wu, K., Lou, D.-F., Peng, C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.065 · Cited by 6
Privacy-Preserving-Enabled Lightweight COVID-19 Simulation Model for Mobile Intelligent Application
Zhang, S., Bi, G., Qi, J., Yang, Y., Kong, X., Nan, F., Zhou, M., & Yang, P. (2022) · IEEE Internet of Things Journal · doi:10.1109/jiot.2022.3162687 · Cited by 6
Chambers, E. S., Cai, W., Vivaldi, G., Jolliffe, D. A., Perdek, N., Li, W., Faustini, S. E., Gibbons, J. M., Pade, C., Richter, A. G., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00878-0 · Cited by 6
Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines
Rhodes, P., & Parry, P. I. (2024) · International Journal of Risk & Safety in Medicine · doi:10.1177/09246479241292008 · Cited by 7
Patel, S., Wu, E. Y., Mundae, M., & Lim, K. K. T. (2022) · Rheumatology & autoimmunity · doi:10.1002/rai2.12042 · Cited by 6
“These trials demonstrated more than 90% efficacy in preventing severe disease and few side effects.(3,4) In addition to administering vaccines, countries around the world implemented their own public health measures, such as increased testing rates, school closures, and face‐covering requirements.”
BackgroundPraktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe
Klimek, L., Bergmann, K., Brehler, R., Pfützner, W., Worm, M., Hartmann, K., Jakob, T., Novak, N., Ring, J., Hamelmann, E. H., et al. (2021) · Allergo Journal · doi:10.1007/s15007-021-4773-1 · Cited by 7
Waning COVID-19 vaccine effectiveness in Japan.
Kurita, J., Sugawara, T., & Ohkusa, Y. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01000 · Cited by 5
“Vaccine efficacy was estimated as 95% through clinical trials (25).”
BackgroundMultifocal motor neuropathy after SARS-CoV-2 vaccination: a causal or coincidental association?
Eren, F., Aygül, R., Tenekeci, S., & Öztürk, Ş. (2022) · Journal of International Medical Research · doi:10.1177/03000605221110709 · Cited by 6
“Potential side effects associated with vaccination include pain, fatigue, fever, and allergic reactions.(3) A few cases of Guillain–Barr e syndrome (GBS) have been reported after SARS-CoV-2 vaccination.”
BackgroundLázaro‐Gorines, R., Pérez, P., Heras‐Murillo, I., Adán‐Barrientos, I., Albericio, G., Astorgano, D., Flores, S., Luczkowiak, J., Labiod, N., Harwood, S. L., et al. (2023) · Advanced Science · doi:10.1002/advs.202304818 · Cited by 6
Stone, C. A., Robinson, L. B., Li, L., Krantz, M. S., Kwah, J. H., Ortega, G., Mancini, C. M., Wolfson, A. R., Saff, R. R., Samarakoon, U., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.08.048 · Cited by 6
“RESULTS: We identified 265 patients with dose-1 immediate reactions with 3 phenotype clusters: (1) Limited or Predominantly Cutaneous, (2) Sensory, and (3) Systemic.”
InfluentialWalmsley, S. L., Ravindran, R., Clarke, R., Wouters, B. G., Silva, A., Gingras, A., & Szadkowski, L. (2022) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0011 · Cited by 5
Éruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19
Bekkali, N., Allard, T., Lengellé, C., & Estève, É. (2021) · Therapies · doi:10.1016/j.therap.2021.04.012 · Cited by 6
Faissner, S., Heitmann, N., Rohling, R., Ceylan, U., Bongert, M., Plaza‐Sirvent, C., Marheinecke, C. S., Pedreiturria, X., Ayzenberg, I., Hellwig, K., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864221141505 · Cited by 6
Cardiac magnetic resonance findings in acute myocarditis after mRNA COVID-19 vaccination
Sano, M., Murai, R., Kim, K., & Furukawa, Y. (2022) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2022.01.015 · Cited by 6
“[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreiera ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, et al.”
Severe Acute Hepatitis in Children of Unknown Etiology
Ng, V. L., Science, M. E., Feld, J. J., Shah, H., Bitnun, A., Bourns, L., Campigotto, A. J., Cohen, E., Gubbay, J. B., Jiménez‐Rivera, C., et al. (2022) · doi:10.47326/ocsat.2022.03.63.1.0 · Cited by 7
A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines
Banerjee, S., Banerjee, D., Singh, A., & Saharan, V. A. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02247-3 · Cited by 7
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.